Form 4: Verastem Director Michael Kauffman Receives Significant Equity Grants

Verastem, Inc. Director Michael Kauffman was granted 8,333 Restricted Stock Units (RSUs) and 12,500 stock options, aligning his interests with shareholders through performance-based vesting.

Summary

• Michael Kauffman, a Director at Verastem, Inc. (VSTM), reported new equity grants on May 22, 2025.
• He acquired 8,333 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.00 per share.
• Following this transaction, Mr. Kauffman beneficially owns 17,216 shares of Common Stock.
• Additionally, he acquired 12,500 stock options with an exercise price of $7.48 per share.
• The stock options have an expiration date of May 22, 2035.
• Both the RSUs and stock options are subject to a vesting schedule of twelve equal installments.
• The first eleven installments will vest monthly from June 2025 to April 2026.
• The final installment will vest on the earlier of the day before the 2026 Annual Meeting of Stockholders or May 31, 2026.
• Vesting is contingent upon Mr. Kauffman's continued service as a director of Verastem, Inc.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates standard corporate governance practices and aligns director interests with shareholders, but it does not provide new information about the company's operational or financial performance.

Positives

• The grant of RSUs and stock options to Director Michael Kauffman aligns his financial interests directly with the long-term performance and shareholder value of Verastem, Inc.
• Equity compensation is a standard practice for retaining and incentivizing key management and directors, promoting commitment to the company's success.

Risks

• The vesting of both RSUs and stock options is conditional upon Michael Kauffman's continued service as a director of Verastem, Inc., meaning unvested portions would be forfeited if his service ceases before full vesting.

Future Outlook

The equity grants to Director Michael Kauffman are structured with a vesting schedule extending through May 2026, contingent on his continued service, indicating an expectation of his ongoing contribution to the company's governance and strategic direction.

Industry Context

The granting of Restricted Stock Units and stock options to directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries, as well as across public companies generally. This form of compensation is used to attract, retain, and incentivize experienced professionals by aligning their long-term financial interests with those of the company's shareholders. It reflects a standard approach to corporate governance and executive compensation.

Comparison to Industry Standards

• Equity compensation for directors, including RSUs and stock options, is a standard practice across the biotechnology and pharmaceutical sectors, similar to companies like Biogen Inc. or Moderna, Inc., which frequently use such instruments to incentivize their leadership.
• The vesting schedule, tied to continued service, is typical for director compensation plans, ensuring long-term commitment, comparable to structures seen in many S&P 500 companies' governance frameworks.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The RSUs and stock options granted to Michael Kauffman will vest in twelve equal monthly installments, beginning in June 2025 and concluding by May 31, 2026, or earlier based on the 2026 Annual Meeting of Stockholders, provided he continues to serve as a director.

Key Dates

Keywords

Verastem, VSTM, Form 4, insider transaction, equity grant, Restricted Stock Units, RSU, stock option, director compensation, beneficial ownership